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Abstract: Today, one of the trends of the pharmaceutical, cosmetic and food market 
is the development of products with components of natural origin, rationally 
exploiting biodiversity. Brazilian population makes secular use of medicinal plants 
including andiroba, whose oil is used in folk medicine as febrifuge, pain-relieving, 
anti-parasitic, anti-allergic as well as insect repellant. The present study attempts 
to evaluate the profile of utilization of andiroba by analyzing the patenting trends 
based on information collected on the databases of the World Intellectual Property 
Organization, European Patent Office and Brazilian National Institute of Industrial 
Property in the period from 1990 to 2011. The following parameters were analyzed: 
chronological aspect of the applications, countries of priority, international patent 
classification, technologies and actors in the technological platform. The temporal 
analysis of the applications shows an evident increase despite a discontinuous 
evolution of the number of applications. Pharmaceutical, chemical and cosmetic 
areas were identified as the main areas for commercial application of the plant. 
Brazil is the country with the largest number of applications even though the 
majority of the patent technologies are already in public domain, indicating that the 
technological information contained in these documents could be used for research 
and investment in several areas.
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Introduction
 The term biodiversity, which is a shortened form 
of the term biological diversity, comes from the Greek 
bios, meaning life, therefore refers to the variety of life on 
Earth. It was fi rst used by the U.S. Offi ce of Technology 
Assessment in 1987 (U.S. Congress, 1987) and since then, 
both the term and the concept have been widely used.
 The concept of biodiversity was discussed on 
the international scenario at the World Conference on 
Environment and Development, organized by the United 
Nations, in Stockholm in 1972. However, the consolidation 
of the term occurred only in 1992 when it was defi ned 
the concept of biological diversity in the Convention on 
Biological Diversity (CBD). The CBD was signed during 
the United Nations Conference on Environment and 
Development (ECO-92), held in the city of Rio de Janeiro 
from 5th to 14th July 1992, and brought a new approach on the 
issue of biodiversity as regarding access and use of genetic 
resources, access to technology and access to benefi ts from 
the use of biodiversity. It was the fi rst global agreement on 
the conservation and sustainable use of all components of 
biodiversity - genetic resources, microorganisms, animal 
and plant species and ecosystems, being considered the 
fi rst legal document that defi nes biodiversity in the context 
of environmental, social and economic issues (Prip et al., 
2010).
 Brazil is the country with the largest plant 
diversity of the planet, considered megabiodiversity, and 
almost 13% of the estimated 1.9 million species of plants 
known today are found in Brazil. The Amazon represents 
7% of the planet's surface and is home to an estimated 50% 
of the global biodiversity, with more than 55 000 species 
of plants, which are equivalent to 22% of  all the species 
already cataloged worldwide (Prance, 1977).
 Today, one of the trends of the pharmaceutical, 
cosmetic and food market is the development of products 
with the largest number of components of natural origin, 
especially those of plant origin, rationally exploiting 
Brazilian biodiversity.
 Furthermore, according to the World Health 
Organization (WHO), approximately 80% of the world’s 
population depends on traditional medicine to meet their 
needs of primary health care and much of this traditional 
medicine involves the use of medicinal plants, their 
plant extracts or their active principles (IUCN, 1993). 
This situation is more evident in developing countries, 
including Brazil, where most of the population has no 
access to medicines and makes secular use of plants as 
for example unha-de-gato, guaco, carqueja, camomila and 
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andiroba, all included in the National List of Medicinal 
Plants of Interest of the Ministry of Health.
 Two species of the Meliaceae family, which is 
comprised of 50 genera and approximately 575 species, 
Carapa guianensis Aubl. and Carapa procera DC 
(Pennington et al., 1981) are popularly known in the 
Amazon under the name andiroba. Despite andiroba, 
this tree is also known by several other popular names, 
including carape, jandiroba, karapa (in South America) 
and crabwood (England). 
 Andiroba, a word from tupi-guarani origin which 
means bitter taste, is a tree that reaches up to 30 m tall, 
with white flowers, slightly fragrant, round fruits, large and 
dark leaves and seeds of brown coloring and angular side 
(Enriquez et al., 2003). The tree is widely distributed along 
the Atlantic coast of Central America; in South America 
from Colombia to Brazil, Ecuador and in Amazonian Peru 
(Pennington et al., 1981).
 Aublet was the first to describe the tree in 1775, 
in Guyana. Its use spread to Guatemala, Peru, Colombia, 
Panama, Venezuela, reaching Brazil, where it was 
developed the first andiroba oil industry, specifically in the 
city of Cametá in the state of Pará (Leite, 1997). This tree 
has multiple uses, being the wood and the oil extracted 
from the seeds the most important products. The oil is one 
of the best selling medicinal products on Amazon, with 
an international demand, being exported to Europe and to 
the United States. However, there are no large areas for 
cultivation, and oil extraction is done by small groups of 
families who harvest the fruits.
 The andiroba oil is thick, dark yellow in 
color and is used for illumination and in the cosmetics 
industry for lotions, shampoos, creams and soaps. It is 
also used in folk medicine as febrifuge, pain-relieving, 
anti-bacterial and anti-parasitic, as well as to treat 
infections of the upper respiratory tract, dermatitis, 
abrasions (Tropical Plant Database, 2012). Its anti-
allergic (Penido et al., 2006a), anti-inflammatory 
(Penido et al., 2006b) and antiplasmodial (Miranda Jr 
et al., 2012) properties have been well documented. 
In the homeopathic pharmaceutical industry, where it 
has been marketed in capsule form, the oil is used for 
diabetes and rheumatism, as well as in the manufacture 
of medicinal soaps. Moreover, according to popular 
markets’ sellers this oil presents a supposed sunscreen 
activity, protecting the skin from sun damage and 
therefore it could be used for the prevention of skin 
cancer. However, a recent work showed that the 
andiroba oil did not present photoprotective activity 
(Ferrari et al., 2007). The residues left over seed oil 
extraction are popularly used for the manufacture of 
insect repellants candles, especially the Anopheles 
mosquitoes that transmit malaria and Aedes aegypti 
that transmits dengue (Mendonça et al., 2005).  
 As a result of the commercial and economic 
importance of products originating from biodiversity, there 
is a growing concern of the companies and universities 
or research centers with protective procedures related to 
the technologies involved in the manufacture of these 
products, particularly the patenting process. 
 A patent is a right granted by the State to the 
authors of inventions that temporarily prevents others 
from economically exploiting an invention without 
permission of the owner. The system aims to reward 
the inventor of a new technique industrially applicable, 
granting him the exclusive right to the exploration of that 
invention for a specified period, in all countries where the 
patent was granted (Abrantes, 2011). 
 In addition to conferring legal protection against 
improper commercial exploitation, the published patent 
document provides information about new technologies, 
helping both directing investments within a particular 
technological field of interest, and determining lines 
of research that should be adopted to reach new market 
niches. The technological information disclosed in patent 
documents is considered a tool for prospecting and 
identifying new business, markets and technologies in 
order to identify threats and opportunities and anticipate 
scenarios changes. 
 With regard to patent protection of biodiversity 
assets, the CBD ensures sovereignty over genetic 
resources of its member countries and the ability to limit 
or prohibit the patenting of living organisms. Both the 
process of extraction/isolation of products from plants 
and the composition containing the extract, substance or 
mixture provided it does not represent a mere dilution can 
be patented. However, Brazilian law forbids patenting 
plants per se and products arising from the isolation and 
purification of natural products such as extracts of plants. 
 In view of the growing interest and the potential 
use of medicinal plants, including andiroba, along with 
the great number of information about new technologies 
that can be found in patent documents and used in the 
development of novel products, the present study attempts 
to evaluate the profile of utilization of andiroba by analyzing 
the patenting trends based on information collected on the 
databases of the World Intellectual Property Organization, 
European Patent Office and Brazilian National Institute 
of Industrial Property (INPI) in the period from 1990 to 
2011.
Material and Methods
Patent search
 The search of patent documents was conducted 
in the following databases: PATENTSCOPE (the 
WIPO database), Esp@cenet (the European Patent 
Office database) and at the database of the Brazilian 
National Institute of Industrial Property (INPI). The 
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PATENTSCOPE is a public database, available on the 
WIPO web portal, and gives access to patent applications 
filed under the Patent Cooperation Treaty (PCT) and to 
patent documents of participating national and regional 
patent offices. The basis of the European Patent Office, 
worldwide base of open access, periodically imports 
documents from more than eighty countries. The basis 
of the INPI is the Brazilian patent basis that contains 
data of patent applications filed and published in 
Brazil. The databases of WIPO and the EPO allow a 
deep research, because in most cases the documents are 
fully available.
 The search strategy used was the "scientific 
name and/or common name of the plant", considering the 
combined fields of the abstract and/or claims. The claims 
define the scope of protection granted by the patent. The 
scientific names used in this work were Carapa guianensis 
and Carapa procera; the common names used were 
andiroba, andirobinha, andiroba-saruba, andiroba-branca, 
andiroba-do-igapó, andirava, aruba, saruba, carapa, 
andirova, cedro-macho, fiqueroa, tangaré, a. vermelha, 
angirova, comaçari, mandiroba, yandiroba, carapá, 
carapinha, gendiroba, jandiroba, penaiba, purga de Santo 
lnácio, abomidan, caraba, canapé, caoba bastarda, caoba 
brasileira, castanha mineira, carape, genriroba, iandirova, 
nhandiroba, karapa, krappa and crabwood. 
 The documents found were analyzed in order to 
remove those duplicated and the applications belonging 
to the same family, obtained more than once due to the 
independent applications at different institutions of 
industrial property.
 The search period was delimited from the WIPO 
database, with applications filed since 1990. The same 
period (i.e. from January 1990 to October 2011) was used 
for searches at the Esp@cenet and INPI basis in order to 
standardize them.
Analysis of the data in patent applications
 In this work, the following analyses were carried 
out:
 • Number and date of deposit;
 • Number and date of priority;
 • Title;
 • Abstract;
 • Applicant profile;
 • Inventor;
 • International Patent Classification (IPC);
 • Object of the patent application;
 • Technology focus;
 • The ratio of patents granted to total number of 
applications.
 Particularly in relation to patent documents 
retrieved from the INPI basis, other information was 
considered for an analysis of the course of the processes. 
The results obtained allowed the analysis even though 
conclusions are limited to the period specified in the 
search.
Results and Discussion
 The search of patent documents yielded 
114 applications filed on the three databases, WIPO, 
Espacenet and INPI, in the period from 1st January 
1990 to 31st October 2011. Table 1 shows the number 
of applications retrieved in each database, including 
applications whose purpose was the protection of the 
plant itself, the association of the plant with other plant 
species or extracts obtained from the plant. The largest 
number of applications was found using the term 
andiroba, which is the main popular name by which 
Carapa is known. 
Table 1. Number of patent applications for Carapa guianensis 
retrieved in each database in the period from 1st January 1990 to 
31st October 2011.
Situation
    Database
WIPO Espacenet INPI Total
Filed 54 24 36 114
Granted 02 05 02 09
 In only 32 of the applications retrieved (28.1 %) 
the use of the plant is the object of protection (Figure 1). In 
most applications, the plant is not the essential component, 
but only a small part of a composition that uses several 
plant extracts or vegetable oils. The results shown below 
consider only these 32 applications.
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Figure 1. Total number of patent applications for Carapa 
guianensis retrieved in WIPO, Espacenet and INPI 
databases. 
 Figure 2 shows the temporal evolution of the 
applications, excluding those not yet published due to the 
statutory 18-month period for a public disclosure. One 
can observe a certain balance in the trend of patenting, 
with the years of 1998 and 2005 with the largest number 
of applications, with 10 and 6, respectively. Despite this 
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discontinuous evolution of the number of applications, 
there was an evident increase, which could be due to a 
growing consumer demand for products containing natural 
ingredients. Moreover these results suggest the importance 
of the patent system as a mechanism for the protection of 
research results related to the use of plants.
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Figure 2. Temporal evolution of patent applications for Carapa 
guianensis retrieved in WIPO, Espacenet and INPI databases, 
considering the applications where the use of the plant is the 
object of protection.
 A particular feature for a patent application 
is the classification according to the different areas of 
technology to which it relates, following the International 
Patent Classification (IPC), which allows the evaluation 
of the technological activity developed by the applicant. 
We then attempted to identify the subclasses of the IPC 
with the higher incidence of applications. As shown in 
Figure 3, there is a concentration in similar technological 
areas, as is the case of the subclasses A61K, A01N and 
C11B that show a higher percentage distribution of the 
recovered applications. One can observe that, of the 
total number of applications, the vast majority, 69% are 
in the A61K subclass - preparations for medical, dental 
or toilet purposes, covering both products presented 
as a composition (mixture) and processes of preparing 
the composition or processes of treating using the 
composition. The subclass A01N (19%) includes pest 
repellants and biocides, as well as compounds used in 
the preservation of foods or foodstuff; and the subclass 
C11B (6%) relates to the production of fats, fatty oils or 
waxes from raw materials. This study simply analyzed the 
main classification and secondary classifications were not 
considered, therefore any assumptions relating to the use 
and production would only be possible after analysis of 
secondary classifications.
  By analyzing the profile of the filed applications, 
we found that the technological distribution is concentrated 
mainly in the chemical, pharmaceutical and cosmetic 
areas, confirming a commercial interest in the use of this 
plant by these industries. These applications corroborate 
several publications concerning studied effects of andiroba. 
Vendramini et al. (2012) showed the action of andiroba oil 
as an alternative to control the ticks, with similar benefits 
to synthetic acaricides, but less damage to nontarget 
organisms and to the environment. In a recent work, 
Prophiro et al. (2012) demonstrated the potential larvicidal 
activity of C. guianensis oil in wild populations of A. 
aegypti, which are primarily responsible for transmitting 
the dengue virus in the environment. In the pharmaceutical 
field the anti-allergic effects of TNTP, a pooled fraction 
of tetranortriterpenoids, isolated from C. guianensis have 
been demonstrated (Ferraris et al., 2011). Moreover, 
different studies show the wound healing activity of C. 
guianensis in animal models (Nayak et al., 2010; Nayak et 
al., 2011).
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Figure 3. Percent distribution of main IPC subclasses in patent 
applications for Carapa guianensis retrieved in WIPO, Espacenet 
and INPI databases, considering the applications where the use 
of the plant is the object of protection. A61K: preparations for 
medical, dental or toilet purposes; A61P: therapeutic activity of 
chemical compounds or medicinal prepartions; A01N includes 
pest repellants and biocides; C11B relates to the production of 
fats, fatty oils or waxes from raw materials; C11C includes oils 
or fatty acids by chemical modification of fats.
 Figure 4 shows a percentage distribution for the 
technologies in the 32 selected applications. A total of 
eight applications claimed the use of the plant as an insect 
repellant and were grouped in the chemical technology. 
In the pharmaceutical area, for example, the applications 
are related to compositions for the treatment, prevention 
or inhibition of allergic and inflammatory conditions 
(BRPI0402875) and for stimulating cell regeneration and 
promoting angiogenesis (BRPI0501269). 
 Figure 5 shows the number of applicants found, 
distributed among companies (n=15), individuals (n=9) 
and universities and/or research centers (n=8). These data 
suggest an investment in research activities related to the 
use of these plants, both by companies and by universities, 
confirming an interest in the economic potential of 
the research results. We can also observe that there is a 
considerable volume of patent applications by individual 
inventors (28%), which does not necessarily indicate 
scientific research, but rather the interest in the protection 
of traditional knowledge associated with biodiversity, 
which could contribute to the development of researches 
that can result in technologies with market value.
Profile of medicinal plants utilization through patent documents: the 
andiroba example
Luciene F. Gaspar Amaral and Iolanda M. Fierro
Rev. Bras. Farmacogn. Braz. J. Pharmacogn. 23(4): Jul./Aug. 2013720
 
Cosmetic
16%
Pharmaceutical
53%
Chemistry
31%
Figure 4. Percent distribution of main technologies in patent 
applications for Carapa guianensis retrieved in WIPO, 
Espacenet and INPI databases, considering the applications 
where the use of the plant is the object of protection.
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Figure 5. Distribution per main depositor of patent applications 
for Carapa guianensis retrieved in WIPO, Espacenet and INPI 
databases, considering the applications where the use of the plant 
is the object of protection.
 The countries of priority for the patent 
applications and the number of applications by each 
country are shown in Figure 6. The priority country is 
the country where a patent application was first filed, 
even though the applicant may request the priority of the 
application in a country other than the country where he 
lives. Brazil is the country with the largest number of 
applications, with nineteen, followed by France, with 
nine published applications. These data indicate that 
the technologies are being developed, probably in the 
listed countries, since, in general, applicants request 
the priority of the application from their countries of 
residence; or indicate the interest of the first deposit to 
be in the markets of these countries. If the application is 
filed and the privilege is required only in one country, 
Brazil for example, any institution in the world can 
replicate the research and commercialize the resulting 
product, except in the Brazilian territory. 
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Figure 6. Countries of origin of the depositors of patent 
applications for Carapa guianensis retrieved in WIPO, Espacenet 
and INPI databases, considering the applications where the use of 
the plant is the object of protection
 Considering the applications by domestic 
applicants, it is important to have a more detailed analysis 
regarding the Brazilian regions and the information 
in these documents. Most Brazilians are individual 
applicants, which contrasts with the known data from 
developed countries, such as the U.S., where the main 
applicants are private companies. Among universities 
and/or research centers the highlights are the Oswaldo 
Cruz Foundation (Fiocruz) and Universidade Estadual 
de Campinas (Unicamp), confirming that research and 
development of new technologies are still carried out 
by universities and public research centers.
 The applications filed by Brazilians were 
distributed among regions, according to the applicant 
statement. It can be seen by analyzing Table 2 that the 
largest number of applications is concentrated in the regions 
of major research centers, universities and companies, 
such as the Southeast, while other regions still show little 
research on this plant. The North region in particular, 
although having the largest Brazilian biodiversity, has 
a small number of applications, suggesting the need for 
a better interaction among academia, industry and the 
government to facilitate actions enabling research results 
to be protected and to reach the market.
Table 2. Geographical distribution of Brazilian depositors of 
patent applications for Carapa guianensis retrieved in WIPO, 
Espacenet and INPI databases, considering the applications 
where the use of the plant is the object of protection.
States Applications
Rio de Janeiro 10
São Paulo 03
Minas Gerais 02
Paraná 01
Santa Catarina 01
Mato Grosso 01
Unidentified 01
Total 19
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 Table 3 presents some information regarding the 
progress of the applications made by Brazilians, which 
suggests the freedom to operate within these technologies. 
Most applications are already in the public domain, either 
because they have been rejected or were shelved. This 
data indicates that the technological information in these 
documents can be a starting point for universities and 
research institutes, especially in the Amazon region, to 
determine, for example, new research lines that should be 
adopted for the development of new technologies from 
the Brazilian flora, thus achieving new market niches. As 
for the patents already granted in Brazil the number is yet 
negligible - only two - with two other applications still 
being examined.
Table 3. Situation of patent applications for Carapa guianensis, 
considering the applications where the use of the plant is the 
object of protection, filed by Brazilians.
Database Granted Technical examination Rejected Shelved
INPI 2 2 1 6
Espacenet - 7 - -
WIPO 1 - - -
Conclusion
 The interest on traditional uses of plants and their 
products in Brazil has been gradually increasing during the 
last few years resulting in a significant body of publications 
in this area. Nevertheless, there is little incentive by 
institutions to encourage the conversion of research results 
into patents and to use all the information about new 
technologies that can be found in patent documents, which 
can lead to a loss of opportunities for the commercial and 
economic exploitation of biodiversity. 
 The relevance of this study is based on the small 
amount of statistical and qualitative data about protecting 
the use of Brazilian plants through the patent system. 
The analysis of the patent documents allows prospects 
evaluation, the development of technological skills and 
opportunities to work and commercially explore the area.
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